Reverse Payments by Drug Companies: The Supreme Court Declines to Adopt a Bright-Line Test (PDF)

The Federal Trade Commission has long opposed "reverse payments," the practice by which a pioneer drug company selling a brand-name drug pays a generic drug company to not enter the market.


Availability:STOCK
Publisher :LexisNexis Emerging Issues Analysis
Format: Electronic, 3 Pages , PDF

ISBN: 9781422429983

7/3/2013
 
$57.00
Less More




Place International Order
Share